Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Chagas gastrointestinal disease

Rogelio Lopez-Velez, MD, DTMH, PhD
Section Editor
Peter F Weller, MD, MACP
Deputy Editor
Elinor L Baron, MD, DTMH


Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, which is most commonly transmitted by triatomine bugs. The major manifestations are Chagas cardiomyopathy and gastrointestinal disease.

Issues related to Chagas gastrointestinal disease will be reviewed here. Other issues related to Chagas disease, including cardiac disease, epidemiology, diagnosis, and treatment, are discussed in detail separately. (See related topics.)


Gastrointestinal manifestations are the second most common cause of complications due to Chagas disease. The mortality is low, but symptoms can have a considerable impact on quality of life. Among individuals with the chronic indeterminate form of Chagas disease, approximately 20 to 30 percent progress over a period of one to three decades to clinically evident cardiac involvement, digestive involvement, or both.

The likelihood of cardiac or digestive involvement may vary by region [1]. The digestive form is observed more frequently in the countries of the Southern Cone of South America and is rare in northern South America, Central America, and Mexico [2]. A high prevalence has been observed in the central region of Brazil. This geographic pattern is thought to be due to distribution of different T. cruzi genotypes [3].


Both parasite and host factors are thought to influence the development of gastrointestinal manifestations and the severity of disease. Molecular techniques have demonstrated the presence of parasite DNA in digestive tissues, which correlates with inflammatory infiltrate and degree of denervation [4].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: Jun 20, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Rezende JM, Luquetti AO. Chagasic megavisceras. In: Nervous System in Chagas Disease, Pan American Health Organization, Washington 1994. p.149.
  2. Rassi A, Rezende JM, Luquetti AO, et al. Clinical phases and forms of Chagas disease. In: American trypanosomiasis (Chagas disease): One hundred years of research, 1st ed, Telleria J, Tibayrenc M (Eds), Elsevier, Burlington, MA 2010. p.709.
  3. Miles MA, Cedillos RA, Póvoa MM, et al. Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease? Lancet 1981; 1:1338.
  4. da Silveira AB, Arantes RM, Vago AR, et al. Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagasic patients with and without megaesophagus. Parasitology 2005; 131:627.
  5. Vazquez BP, Vazquez TP, Miguel CB, et al. Inflammatory responses and intestinal injury development during acute Trypanosoma cruzi infection are associated with the parasite load. Parasit Vectors 2015; 8:206.
  6. Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326:1444.
  7. Troncon LE, Oliveira RB, Romanello LM, et al. Abnormal progression of a liquid meal through the stomach and small intestine in patients with Chagas' disease. Dig Dis Sci 1993; 38:1511.
  8. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.
  9. Kamiji MM, de Oliveira RB. [Features of Chagas' disease patients with emphasis on digestive form, in a tertiary hospital of Ribeirão Preto, SP]. Rev Soc Bras Med Trop 2005; 38:305.
  10. Rassi A, Rezende JM. [Clinical and radiological evaluation of the esophagus and colon in the acute phase of Chagas disease with Report of three cases of spontaneous remission of esophageal group I aperistalsis]. Rev Soc Bras Med Trop 2011; 44:70.
  11. Souza-Lima Rde C, Barbosa Md, Coura JR, et al. Outbreak of acute Chagas disease associated with oral transmission in the Rio Negro region, Brazilian Amazon. Rev Soc Bras Med Trop 2013; 46:510.
  12. Rezende JM, Moreira H. Forma digestive da Doenca de Chagas. In: Trypanosoma cruzi e Doeca de Chagas, 2nd ed, Brener Z, Andrade ZA, Barral-Neto N (Eds), Guanabara Koogan, Rio de Janeiro 2000. p.465.
  13. Pérez-Ayala A, Pérez-Molina JA, Norman F, et al. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol 2011; 105:25.
  14. Kirchhoff LV. American trypanosomiasis (Chagas' disease). Gastroenterol Clin North Am 1996; 25:517.
  15. Rezende Filho J, De Rezende JM, Melo JR. Electrogastrography in patients with Chagas' disease. Dig Dis Sci 2005; 50:1882.
  16. Meneghelli UG. Chagasic enteropathy. Rev Soc Bras Med Trop 2004; 37:252.
  17. Martini AS, Lopes RA, Utrilla LS, et al. Morphological and morphometric study of the alterations on young mouse parotid gland with subpatent Chagas' disease. Angew Parasitol 1986; 27:65.
  18. Pinazo MJ, Ignacio Elizalde J, de Jesús Posada E, Gascón J. Co-infection with two emergent old pathogens: Trypanosoma cruzi and Helicobacter pylori. Enferm Infecc Microbiol Clin 2010; 28:751.
  19. Mattoso LF, Reeder MM. Radiological diagnosis of Chagas' disease (American trypanosomiasis). Semin Roentgenol 1998; 33:26.
  20. de REZENDE J, LAUAR KM, de OLIVEIRA A. [Clinical and radiological aspects of aperistalsis of the esophagus]. Rev Bras Gastroenterol 1960; 12:247.
  21. Roure S, Valerio L, Vallès X, et al. Oesophageal motility disorders in infected immigrants with Chagas disease in a non-endemic European area. United European Gastroenterol J 2016; 4:614.
  22. Sánchez-Montalvá A, Moris M, Mego M, et al. High Resolution Esophageal Manometry in Patients with Chagas Disease: A Cross-Sectional Evaluation. PLoS Negl Trop Dis 2016; 10:e0004416.
  23. Pinazo MJ, Cañas E, Elizalde JI, et al. Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010; 33:191.
  24. Hernandez EB, Rezende JM, Macedo V, Castro N. Estudo radiológico do cólon em indivíduos de área endemica de doenca de Chagas atraves da técnica simplificada de Ximenes. Rev Soc Bras Med Trop 2002; 35 Suppl III:188.
  25. Salvador F, Mego M, Sánchez-Montalvá A, et al. Assessment of rectocolonic morphology and function in patients with Chagas disease in Barcelona (Spain). Am J Trop Med Hyg 2015; 92:898.
  26. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.
  27. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.
  28. Brant C, Moraes-Filho JP, Siqueira E, et al. Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia. Dis Esophagus 2003; 16:33.
  29. Herbella FA, Aquino JL, Stefani-Nakano S, et al. Treatment of achalasia: lessons learned with Chagas' disease. Dis Esophagus 2008; 21:461.
  30. Cutait DE, Cutait R. Surgery of chagasic megacolon. World J Surg 1991; 15:188.